Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Can Premium-Priced Trulicity Prickle Victoza In India?

This article was originally published in Scrip

Executive Summary

Eli Lilly's once-weekly diabetes therapy Trulicity (dulaglutide) appears to have made its Indian debut priced at a premium compared with certain Western markets –an indication that some innovator firms are less likely to consider major pricing flexibilities in first-wave markets for new products, even if these are emerging economies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register